CKD (6407) Q4 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2026 earnings summary
31 Jul, 2026Executive summary
Net sales rose 1.4% year-over-year to ¥157,886 million, with operating profit up 3.3% to ¥19,640 million and profit attributable to owners of parent up 0.4% to ¥13,578 million.
Growth in the semiconductor-related market, especially for generative AI, offset declines in the automatic machinery segment and automotive-related markets.
Overseas, robust demand in China and steady sales in other regions supported overall performance.
Financial highlights
Gross profit increased to ¥46,845 million from ¥45,199 million year-over-year.
Comprehensive income surged 88.2% to ¥21,841 million, driven by gains in foreign currency translation and available-for-sale securities.
Cash and cash equivalents at year-end totaled ¥42,258 million, up ¥7,913 million from the previous year.
Dividend per share for the year was ¥81, with a payout ratio of 39.9%.
Outlook and guidance
For the fiscal year ending March 31, 2027, net sales are forecast at ¥180,000 million (+14.0% YoY), operating profit at ¥24,500 million (+24.7%), and profit attributable to owners of parent at ¥16,300 million (+20.0%).
Projected annual dividend is ¥95 per share.
The company expects continued growth in semiconductor-related demand and automation solutions, while monitoring geopolitical risks.
Latest events from CKD
- Double-digit sales and profit growth driven by robust demand in key technology sectors.6407
Q1 202531 Jul 2026 - Strong sales and profit growth fueled by semiconductor and battery market demand.6407
Q2 202531 Jul 2026 - Double-digit profit growth and higher dividends, led by robust semiconductor and battery demand.6407
Q4 202531 Jul 2026 - Strong sales and profit growth led to an upward revision of full-year forecasts.6407
Q3 202531 Jul 2026 - Sales and profits fell year-over-year, but full-year guidance is maintained.6407
Q1 202631 Jul 2026 - Profits fell and forecasts were cut as semiconductor demand recovery lags and risks persist.6407
Q2 202631 Jul 2026 - Sales and profits fell, but comprehensive income and assets increased; outlook unchanged.6407
Q3 202631 Jul 2026